Treatment with only MMR or ICB did not improve survival, but combination therapy with both MMR and dual-agent ICB led to significant tumor inhibition (p <0.0001), indicating a synergistic antitumor response (Figure 4B). This evidence concerns the gene MRC1 and neoplasm.